Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor
TJ Barber, L Harrison, D Asboe… - Journal of …, 2012 - academic.oup.com
Background Selection of protease mutations on antiretroviral therapy (ART) including a
ritonavir-boosted protease inhibitor (PI) has been reported infrequently. Scarce data exist …
ritonavir-boosted protease inhibitor (PI) has been reported infrequently. Scarce data exist …
Mutational patterns and correlated amino acid substitutions in the HIV1 protease after virological failure to nelfinavirand lopinavir/ritonavirbased treatments
Human immunodeficiency virus type 1 (HIV1) antiviral drug resistance is a major
consequence of therapy failure and compromises future therapeutic options. Nelfinavir and …
consequence of therapy failure and compromises future therapeutic options. Nelfinavir and …
Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors
UK Collaborative Group on HIV Drug … - Antiviral …, 2008 - journals.sagepub.com
Background In recent years, several new drugs from the protease inhibitor (PI) class
designed to treat HIV infection have become available and the use of ritonavir-boosting has …
designed to treat HIV infection have become available and the use of ritonavir-boosting has …
[PDF][PDF] Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538)
E De Clercq, AM Vandamme - Aids, 1996 - rega.kuleuven.be
Objective: To define genotypic and phenotypic resistance patterns following pro-longed
therapy with the protease inhibitor ritonavir (ABT-538). Design: Seven HIV-1-infected …
therapy with the protease inhibitor ritonavir (ABT-538). Design: Seven HIV-1-infected …
The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease …
M Karmochkine, AS Mohamed, C Piketty, C Ginsburg… - Antiviral research, 2000 - Elsevier
Salvage therapy with ritonavir (RTV) and saquinavir (SQV) failed to achieve virological and
immunological improvement in 24 HIV-infected patients who discontinued triple therapy with …
immunological improvement in 24 HIV-infected patients who discontinued triple therapy with …
Natural polymorphisms in HIV1 protease: Impact on effectiveness of a firstline lopinavircontaining antiretroviral therapy regimen
K Champenois, S DeufficBurban… - Journal of medical …, 2008 - Wiley Online Library
Mutations on HIV protease lead to resistance to protease inhibitors. However, resistance
development may be different according to primary, secondary or polymorphic mutations …
development may be different according to primary, secondary or polymorphic mutations …
Resistance to HIV protease inhibitors: mechanisms and clinical consequences
HIV-1 protease is an aspartic protease composed by two identical monomers, 99 amino
acids in length. Drug resistance is mainly mediated by structural changes in the substrate …
acids in length. Drug resistance is mainly mediated by structural changes in the substrate …
[PDF][PDF] Identification of individual mutations in HIV protease associated with virological response to lopinavir/ritonavir therapy
V Calvez, I Cohen-Codar, AG Marcelin… - Antiviral …, 2001 - medadvocates.org
E011680G Calvez Poster Page 1 q Virologic response in the context of differences in baseline
LPV mutation score, baseline HIV RNA and baseline CD4 is provided in Table 3. Overall …
LPV mutation score, baseline HIV RNA and baseline CD4 is provided in Table 3. Overall …
Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens
Objectives To assess the most frequent resistance-associated mutations (RAMs) to
lopinavir/ritonavir in a cohort of patients attended in daily practice. Methods We …
lopinavir/ritonavir in a cohort of patients attended in daily practice. Methods We …
[HTML][HTML] Next generation sequencing of HIV-1 protease in the PIVOT trial of protease inhibitor monotherapy
DT Dunn, W Stöhr, A Arenas-Pinto, A Tostevin… - Journal of Clinical …, 2018 - Elsevier
Background The PIVOT trial examined whether patients with suppressed viral load on
combination antiretroviral therapy could be safely switched long-term to ritonavir-boosted …
combination antiretroviral therapy could be safely switched long-term to ritonavir-boosted …
相关搜索
- resistance mutations protease gene
- protease inhibitor lopinavir ritonavir
- protease inhibitors hiv 2
- prevalence and patterns protease resistance
- ritonavir and saquinavir protease gene
- individual mutations hiv protease
- virological failure protease gene
- virological response hiv protease
- resistance mutations ritonavir and saquinavir
- salvage therapy protease gene
- resistance mutations salvage therapy
- cumulative occurrence protease gene
- resistance mutations cumulative occurrence
- population trends protease resistance
- protease inhibitors primary isolates
- protease inhibitors prevalence and patterns